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Abstract
In vitro display technologies based on phage and yeast have a successful history of selecting singlechain variable fragment (scFv) antibodies against various targets. However, single-chain antibodies
are often unstable and poorly expressed in Escherichia coli. Here, we explore the feasibility of
converting scFv antibodies to an intrinsically ﬂuorescent format by inserting the monomeric, stable
ﬂuorescent protein named thermal green, between the light- and heavy-chain variable regions.
Our results show that the scTGP format maintains the afﬁnity and speciﬁcity of the antibodies,
improves expression levels, allows one-step ﬂuorescent assay for detection of binding and is a
suitable reagent for epitope binning. We also report the crystal structure of an scTGP construct
that recognizes phosphorylated tyrosine on FcεR1 receptor of the allergy pathway.
Key words: crystal structure, epitope binning, improved expression and functionality, intrinsically ﬂuorescent scFv antibodies,
soluble scFv antibodies

Introduction
Fluorescently labeled antibodies are extensively used in diagnostic
and research methods such as immunofluorescent microscopy and
flow cytometry. The latter allows the rapid and quantitative analysis
of single cells within a large population, and fluorescent-activated
cell sorting (FACS) allows the sorting of individual cells based on
their specific fluorescent patterns. Antibodies used in these assays are
typically labeled with fluorescent chemical compounds. For example,
a succinimidyl ester functional group attached to a fluorophore core

may react with primary amines to label the antibody. However, this
strategy may reduce or eliminate binding if there are primary amines
within the antigen recognition regions (Mccormack et al., 1996).
Different antibodies react with different fluorophores at different
rates, creating variability in experimental settings. Furthermore, since
the labeling is stochastic, some antibodies will have large numbers
of fluorophores and some very few. Fluorophore over-conjugation
can result in quenching and dimmer antibody molecules than those
with less fluorophore conjugation (Haugland, 1995). While standard
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Fig. 1 Schematic diagram depicting examples of antibody formats utilized in
research. Panel A depicts the traditional IgG and panel B depicts the corresponding scFv constructs (in either VH-VL or VL-VH orientation). Examples
for scFv fusion constructs are given in panels C and D. Panel E shows a
nanobody-FP fusion, VH-FP-VL fusion is given in panel F and panel G provides
the concept for the work described here.

modifications utilized in research in comparison to the scTGP format
presented here.
TGP is an extremely stable, highly soluble, non-aggregating green
fluorescent protein that was engineered in our lab (Close et al., 2015)
to overcome the problems of solubility and aggregation with many
traditional GFPs and their variants. TGP was engineered by disrupting crystal lattice contacts and introducing high-entropy glutamate
residues to improve crystallization and prevent oligomerization. The
monomeric nature of TGP makes it potentially suitable for insertion
into scFv genes, substituting the linker originally used to tether the VL
and VH. In this study, we construct single-chain fluorescent proteins
(scFPs) as VL-TGP-VH. These scFPs are fluorescent, are functional
in yeast display technologies and are expressed at high levels in the
bacterial cytoplasm. We describe the construction of scFPs and their
functionality using multiple assays. We use three scFvs and compare
them with the corresponding scTGP formats. The antibodies p11 and p13B1 recognize phosphorylated immunoreceptor tyrosinebased activation motif (ITAM) peptides of FcεR1 receptor of the
allergy pathway (Velappan et al., 2019) and the anti–tyrosine sulfate
antibody recognizes the post-translationally modified tyrosine within
proteins or peptides (Kehoe et al., 2006). We report the X-ray crystal
structure of scTGP p1-1.
Finally, we use scTGP and IgGs to develop a novel epitope binning
method for multimeric proteins. We demonstrate this method using
three antibodies against Yersinia pestis, the causative agent of plague
(Lillo et al., 2011; Lillo et al., 2020). Epitope binning uses competitive
pairwise binding assays to sort antibodies into bins recognizing the
same or different epitopes. Antibodies binned together often have
similar functional activity (e.g. block binding to a cell surface receptor), while those in different bins recognize different epitopes and
consequently may have different functional activities. This proof of
concept demonstrates the utility of the scTGP format for generating
clinically relevant antigen detection tools.

Materials and Methods
Construction of scTGP genes
The scTGP constructs were prepared using inverse PCR and
circular polymerase extension cloning (CPEC) assembly. The vector
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techniques have been developed to perform antibody labeling reactions, batch-to-batch variation and labeling can also affect antibodyantigen recognition (Vira et al., 2010).
One of the most effective methods to develop antibodies is to
select them from large combinatorial libraries using phage and/or
yeast in vitro display technologies (Boder and Wittrup, 1997; Ferrara
et al., 2012; Marks et al., 1991; Sblattero and Bradbury, 2000). As
full-length antibodies cannot be directly displayed easily, Fabs or
single-chain variable fragments (scFvs) (Huston et al., 1988), which
comprise the antibody heavy-chain variable (VH)- and light-chain
variable (VL)-binding domains, can be displayed on phage or yeast
fused to surface display proteins. The scFv genes can be constructed
by connecting VH and VL regions with an unstructured linker peptide
(Huston et al., 1988), or one that comprises a translated DNA recombination signal (Sblattero and Bradbury, 2000). The genes encoding
the variable regions are available during the selection process and can
be reformatted into many different functional modalities (Bradbury
and Pluckthun, 2015).
However, scFvs tend to aggregate, have low expression levels
and are unstable during long-term storage (Arndt et al., 1998). To
monitor binding, scFvs are typically tagged, then detected using an
anti-tag antibody and appropriately labeled secondary antibodies.
Several strategies have been used to overcome these limitations
(Fig. 1), including cloning as full-length antibodies (Persic et al.,
1997) or scFv-Fc fusions (Shu et al., 1993), in which case traditional labeled secondary antibodies can be used. Fusion to enzymatic or fluorescent proteins allows detection without the need for
secondary antibodies. The scFv-alkaline phosphatase (AP) fusions
(Lindner et al., 1997) are stable and functional, allowing single
step detection of bound antibody. Fusion of green fluorescent protein (GFP) or other fluorescent proteins (FPs) to the C terminus
of scFv genes yields intrinsically fluorescent scFv. However, scFvGFP fusions tend to be poorly expressed (Casey et al., 2000). The
scFv folds best in oxidizing environments, such as the bacterial
periplasm or eukaryotic secretory pathway (Kipriyanov et al., 1997),
while most FPs are best expressed in the reducing environment of
the cytoplasm. A notable exception is superfolder GFP (Pédelacq
et al., 2006). This expression incompatibility has been overcome
by fusing a short tag derived from split GFP to the C terminus
of the scFv (Ferrara et al., 2011) and carrying out the complementation in vitro, fusing GFP to particularly stable scFvs (Nizak
et al., 2003), or creating nanobody FP fusions (Rothbauer et al.,
2008).
Markiv et al. (2011a,b) described an alternative concept to generate fluorescent scFvs in which the FP was placed between the VH and
VL as a linker (VH-FP-VL) and could be expressed in the bacterial
cytoplasm. The fluorescent proteins used included mRFP1 (derived
from DsRed), BFP, mCerulean and mCitrine to produce red, blue,
green and yellow antibodies. The alternative orientation, VL-VH,
was not attempted. Chain orientation may be important in binding
properties, and the strategy described in that publication may not be
compatible for scFv libraries constructed in the VL-linker-VH orientation. Markiv et al. (2011a,b) use the term REDantibody in their first
description of the technology. However, no specific terminology was
used in the subsequent paper when additional fluorescent proteins
were tested (Markiv et al., 2011a,b). Here we refer to the concept of
fluorescent antibodies created using a fluorescent protein as a linker
as single-chain fluorescent protein (scFP), with specific formats called
out for individual scFPs, e.g. scTGP for the scFPs described here in
which the thermal green protein (TGP) (Close et al., 2015) is used
as a linker. Figure 1 provides a visual summary of exemplar scFv
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of influenza A was used as non-specific antigen (MSLLTEVETPIRNEWGCRCNDSSD). The yeast (100–200 μl) were first washed
with yeast wash buffer (YWB—30 mM Tris pH 8.0 with 0.5% BSA),
by centrifugation at 13 000g. The binding assays were performed
using 100 nM peptide antigens diluted in YWB and incubated for
1 h at room temperature with rotation. Unbound peptide was washed
away using YWB. The antigen bound yeast was further stained
with anti-SV5 PE (1 μg/ml) and streptavidin labeled with Alexa
633 (S21375, ThermoFisher Scientific, 5 μg/ml) for biotinylated
peptide detection. Washes with YWB were conducted to improve
specificity of binding. All incubations and washes were performed
at room temperature. The yeast display analysis was performed
using FACS Aria and/or LSR II cytometers (Becton Dickinson). For
each flow cytometry analysis, 10 000 events were collected and
average value was used to report mean fluorescence intensity (MFI)
for display level and binding signal and the assays were repeated
multiple times to ensure accuracy. Experiments were performed in
triplicates to measure the Kd values. Affinity measurements were
conducted by serial dilution of the biotinylated peptide antigens as
described previously (Ferrara et al., 2012; Velappan et al., 2019).

Yeast display analysis

Protein expression in bacteria

Yeast display plasmids (based on pDNL6) (Ferrara et al., 2012) were
transformed into Saccharomyces cerevisiae EBY100 and cloned by
gap repair using the Yeast1 kit (Sigma Inc.). In this vector system,
the scFvs are fused to the C terminus of the AGA2 protein of the
yeast for surface display and the SV5 peptide tag is used to assess
display levels on yeast. The transformed yeast were grown in SD/CAA
(5 g/l casamino acids (−ade, −urs, −trp), 20 g/l dextrose, 1.7 g/l yeast
nitrogen base, 5.3 g/l ammonium sulfate, 10.19 g/l Na2 HPO4 .7H2 O
and 8.58 g/l NaH2 PO4 ) agar plates at 30◦ C for 2 days. Single
colonies were further grown in SD/CAA liquid culture at 30◦ C until
the culture reached an OD600 of >2. 1/10th volume of this culture
was added to SG/R CAA media (same as selective media except
substitute the following sugars for dextrose: 20 g/l galactose, 20 g/l
raffinose, 1 g/l dextrose) and induced at 20◦ C as described previously
(Ferrara et al., 2012). Yeast inductions were allowed to proceed for
2 days to further improve display of scTGP.
After induction, yeast cells were incubated with phycoerythrin
(PE) conjugated anti-SV5 IgG (1 μg/ml) to assess scFv/scTGP display levels. In the case of scTGPs, the display levels were also
assessed using the fluorescence at 530 nm when excited using 488 nm
laser. The time course experiment reported in Supplementary Fig.
S1, available at PEDS online, was performed with three different
colonies of yeast from each of constructs. For analysis on three
consecutive days post-induction, 100 μl of yeast was taken, fluorescence of yeast was analyzed using flow cytometry and average
fluorescence along with standard deviation from these replicates was
calculated.
Antibody p1-1 (Velappan et al., 2019) recognizes a 25 amino acid
peptide that corresponds to the ITAM region of the FcεR1 receptor
of mast cells when the first tyrosine of this peptide is phosphorylated,
and peptide was named p1 (KVPDDRLYEELHVYSPIYSALEDTR,
the phosphorylated tyrosine is bold and underlined). Antibody
p13B1 (Velappan et al., 2019) recognizes the same peptide
when all three tyrosines are phosphorylated and designated as
p123 (KVPDDRLYEELHVYSPIYSALEDTR). The M2 peptide

All genes were cloned into the vector systems described below, using
restriction enzymes BssH II and Nhe I (R0199 and R3131, New
England Biolabs). The scFv and scTGP genes were both cloned into
pEP, a periplasmic expression vector, while the scTGP constructs
were also cloned into pETCK3, a cytoplasmic expression system. The
protein expression in both plasmid systems is controlled by the T7
promoter system.
To produce scFvs and scTGPs, bacterial colonies were streaked
on LB kan/glu (kanamycin 50 μg/ml and glucose 3%) plates and
incubated at 37◦ C overnight. A second overnight culture was grown
in 1–10 ml of LB media containing kanamycin and glucose. Liquid
culture was grown at 30◦ C. The overnight culture volume was
set to 1/10th final expression culture volume. The following day,
the overnight culture was diluted to half the final culture volume
and grown in kan/glu media at 30◦ C for 2 h. The culture was
centrifuged (6000g for 6 min) and the pellet was re-suspended in
auto-induction (AI) media containing kanamycin (Studier, 2005). AI
media allows protein induction without the use of isopropyl β-d-1thiogalactopyranoside (IPTG). Here, glucose, glycerol and lactose are
added to buffered yeast broth growth media. As the Escherichia coli
cultures grow, they consume glucose first. As the glucose depletes, the
bacteria are forced to utilize lactose inducing the T7 promoter and
allowing protein production. The culture was incubated at 30◦ C for
4 h. Subsequently, the temperature was reduced to 18◦ C and protein
expression continued for 2 days (scFvs) or up to 3 days (scTGPs).
The cell culture was spun down (10 000g, 20 min) and frozen prior
to protein purification. Three colonies from each of the constructs
(scFv-pEP, scTGP-pEP, scTGP-pET) for antibodies p1-1 and p13B1
were used to analyze functionality of proteins expressed in different
bacterial compartments. About 1 ml of expressed culture was spun
down and the bacterial pellet was lysed using 1/10 POP culture
reagent (71092, EMD Millipore). Incubation time was 30 minutes
at room temperature and the insoluble fraction was separated by
centrifugation (20 000g at 4◦ C). About 100 μl of cell culture was used
to measure the fluorescence of pre-lysed culture and 100 μl of POP

®

Kd determination was performed using GraphPad Prism software
using the equation for one site-specific binding, which uses non-linear
regression analysis to fit the curve.
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was amplified using scFv linker–specific primers DCO 111 (TCCTCAAGCGGTACCCAGGTGCA) and DCO 112 (TCTGGAGGGTCGACCATAACTTCG). This primer combination was used to amplify
the yeast display vector as well as the bacterial expression plasmids
containing the scFv gene(s). The TGP gene was amplified using
DCO 109 (TCTGGAGGGTCGACCATAACTTCGGTAATTAAACCGGAAATGAAAATTAAATTGCG) and DCO 110 (TATTCTGGCGGAGGCAGCGGATCCTCAAGCGGTACCCAGGTACA). Q5
polymerase (M4091, New England Biolabs) was used for all
amplification reactions according to manufacturer’s instructions.
Both vector and insert were gel purified prior to CPEC assembly.
CPEC assembly was performed by combining equimolar amounts
of vector and fluorescent protein insert and reducing the annealing
temperature gradually from 70 to 55◦ C using 10 s intervals. Upon
completion of the CPEC assembly, the reaction was purified using
a mini-elute column (28004, Qiagen Inc.). The constructs were
eluted into 10 μl of 1:2 elution buffer: water and transformed via
electroporation to bacterial cells. Yeast display constructs were
transformed into Omnimax T1 or TOPO 10 cells (C854003 or
C4044003, ThermoFisher Scientific) according to manufacturer’s
instructions and bacterial expression plasmids were cloned into BL21
DE3 (archival samples LANL) cells. Constructs were verified by DNA
sequencing after cloning.

4

Protein puriﬁcation
The bacterial pellets were re-suspended in TNG buffer (50 mM
Tris pH 8.0, 150 mM NaCl, 10% v/v glycerol) containing DNase
1 (PI89836, Thermo Fisher Scientific) and EDTA-free protease
inhibitor tablet (11873580001, Roche Inc.). Cell lysis was achieved
using a cell homogenizer (Avestin Inc.). The lysate was spun at
13 000g and the supernatant was then spun at 38 000g and filter
sterilized to remove cell debris. Protein purification was performed
using Ni-NTA agarose beads. The His-tagged proteins were allowed
to bind to the beads for 1 h at 4◦ C with rotation. The beads
were washed with 5–10× volume of TNG buffer and TNG buffer
containing 20 mM imidazole. Proteins were eluted with TNG buffer
containing 250 mM imidazole. The protein was cleaved from the
His-tag with TEV protease using 0.5–1 mg of TEV protease and the
digestion proceeded in a dialysis cassette in TEV buffer (20 mM Tris
[pH 8.0], 100 mM NaCl, 0.5 mM EDTA, 3 mM reduced glutathione)
at RT, overnight. The His-tag fragment and any uncleaved protein
were subsequently removed by a second pass through fresh Ni-NTA
agarose beads. Protein concentration and purity were determined
using protein electrophoresis and Coomassie staining, absorbance at
280 nm or using fluorescence intensity. Prior to crystallization, scTGP
proteins were further subjected to chromatography on a 320 ml XK
26/60 Sephadex 200 size-exclusion column using an AKTA prime
liquid chromatography system (GE healthcare). Fluorescent protein
fractions were collected and assessed using gel electrophoresis and
Coomassie staining for purity. Pure fractions were combined and
concentrated using Amicon centrifugal filters with 30 kDa cutoff.
Protein expression for these constructs was conducted multiple
times during the course of the project to ensure consistency once
the protocol was established. A typical protein expression volume
was 1 L followed by FPLC purification.

ELISA and FLISA assays
Neutravidin- (31000, Thermo Fisher Scientific) coated wells (100 μl
of 10 μg/mL in PBS) were used in both enzyme-linked immunosorbent
assay (ELISA) and FLISA (Velappan et al., 2008) to bind biotinylated antigens. Nunc maxisorp plates (12-565-136, ThermoFisher
Scientific) and black maxisorp plates (43711, Nunc) were used for
FLISA. The peptide antigens were synthesized with biotin at the
N terminus and protein antigens were biotinylated using EZ-Link
NHS-LC-LC-biotin (21343, Thermo Fisher Scientific) according to
manufacturer’s protocols. The wells were washed with PBS and
blocked with blocking agent containing 2% milk (ELISA) or 2%
BSA (FLISA) for 30 mM TRIS pH 8.0 was used as the buffer instead
of PBS in binding assays with ITAM peptides. About 1 μg of bioantigen in 100 μl was added to blocked wells and was allowed to
bind to neutravidin for 15 min while shaking. Excess antigen was
washed off and equal amounts of scFv and scTGP antibodies were
added in blocking buffer diluted to 10% in PBS. Antigen-antibody
interactions were allowed to proceed for 1.5 h and excess antibody

was washed with PBST (1× PBS, 0.1% tween) three times followed by
three washes with 1× PBS. For ELISA, anti-SV5 antibody conjugated
to horse radish peroxidase (HRP) was used as secondary reagent. The
bound HRP was detected using its substrate TMB (T8665, Sigma
Inc.) and the absorbance at 450 nm was read after quenching with
1 M H2 SO4 . For FLISA, fluorescence was directly measured after
washing with excitation set at 488 nm and emission set to 530 nm. All
binding assays were performed in triplicate and average values and
standard deviation were calculated. We repeated the binding assay for
p1-1 and p13B1 scFv and scTGP proteins at equimolar concentration
(50 nM of antibody). The assay was performed as described above.

Crystallization and structural determination
The scTGP p1-1 was crystallized using the sitting drop vapor diffusion method. Protein (10 mg/ml) and reservoir solutions of 0.1 μl each
were mixed and equilibrated against 30 μl reservoir at 298 K using a
PHOENIX crystallization robot (Art Robbins Instruments). A set of
crystallization reagents consisting of Crystal Screens, PEG/Ion screens
(Hampton Research), PACT suite (Qiagen), and JCSG core suites
(Qiagen) was used to screen for the propensity of crystallization.
Subsequent grid screens to optimize buffer pH, concentrations of
salt and precipitants, and additive screens were employed as needed
until diffraction-quality crystals were obtained. Crystals of scTGP
were harvested with CryoLoops (Hampton Research) and flashcooled in liquid nitrogen prior to diffraction experiments. Glycerol
was added to the mother liquor as cryo-protectants to final concentrations of 5–20% for conditions that were not cryo-ready. XRay diffraction experiments were conducted at the 5.0.2 beam line
at the Advanced Light Source at the Lawrence Berkeley National
Laboratory. The crystal structure of scTGP was determined with the
molecular replacement (MR) method using the PHASER program
(Mccoy et al., 2007) in the PHENIX suite (Liebschner et al., 2019).
The TGP structure (PDB ID: 4TZA) (Close et al., 2015) was used as
a search model to locate the TGP moiety of the scTGP. The rest of
the protein chain was modeled with the AutoBuild (Terwilliger et al.,
2008) program in Phenix. Manual model rebuilding and refinement
was conducted iteratively until convergence with Coot (Emsley et al.,
2010) and phenix.refine (Afonine et al., 2012), respectively.

Epitope binning using competitive FLISA with scTGPs
and IgGs
The anti-F1 scTGPs were constructed by PCR from scFvs (YP 1,
2, 3, 4, 6, 8) (Lillo et al., 2011) as described above and cloned
into the pETCK3 protein expression vector for expression in BL21
E.coli. Protein expression, purification, quantification and binding to
specific antigen (biotin-F1V) and control antigen (biotin-myoglobin)
were performed with FLISA as described above. FLISA with gradient protein concentration (2×) starting at 20 000 ng in 100 μl
volume/well was used to determine the binding curve of scTGP YP2,
YP3 and YP8 (these antibodies were determined to be the most
functional antibodies in this suite). The corresponding anti-YP IgGs
were synthesized at ATUM Inc. and the F1V recognition by these IgGs
was evaluated by ELISA using anti-human HRP (97165, Abcam)
as the secondary antibody (Lillo et al., 2020). The epitope binning
assay was performed similarly to FLISA. Here, the biotinylated F1V
protein was bound to neutravidin-coated black immunosorp plates
(8 wells/sample) and scTGP (5000 ng) was added to all wells.
The binding proceeded for 30 minutes without washing while the
titrations of the IgGs were performed. IgG concentrations ranging
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culture supernatant was used to measure fluorescence post-lysis. The
cytoplasmically expressed scTGP had higher fluorescence than the
periplasmically expressed scTGP. Fluorescence-linked immunosorbent assay (FLISA) was performed with two normalizations: equal
volume or equal fluorescence. Here, 100 μl of post-lysis supernatants
or volume of supernatants adjusted to provide equal fluorescence was
used. Both expression and binding assays were performed in triplicate
and average values and standard deviations were calculated. A twotailed T-test was used to compare the two expression systems.
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Table I. Comparison of scFv and scTGP formats
scTGP p1-1

scFv p13B1

scTGP p13B1

9111
4696

1280
283

10 215
4882

5168
893

160

127

160

118

142

115

112

154

2.43 ± 0.22

8.55 ± 2.33

1.40 ± 0.65

0.51 ± 0.56

The table compares amount of protein displayed by the yeast, recognition signal for the specific peptide antigen, non-specific interaction signals and affinity of
binding by two antibodies (p1-1 and p13B1) in both scFv and scTGP formats

from 0.75–50 μg were used. One well contained scTGP only. The
titrated IgG solutions were added to the wells and incubated for
30–60 min. The unbound molecules were washed using PBST/PBS
and the fluorescence of the bound scTGPs was measured using
a spectrophotometer with excitation at 488 nm and emission at
530 nm. A decrease in fluorescence or lack thereof was used to
determine presence or absence of different epitopes. Duplicate assays
were performed to calculate average values and standard deviation
was used to determine error bars.

Results
Comparison of scFv and scTGP constructs by yeast
display
Three scFvs were used to test TGP in the scFP construct in the
VL-VH orientation: p1-1 and p13B1 are two antibodies previously
selected against different phosphorylation states of the cytoplasmic
domain of the Fc-epsilon receptor (Velappan et al., 2019), and αTyrS
is an antibody that recognizes the sulfotyrosine post-translational
modification, independently of sequence context (Kehoe et al., 2006).
Figure 2 and Table I together show that p1-1 scTGP and p13B1
scTGP were displayed on the yeast surface and recognized their
cognate peptide antigens. Figure 2 shows flow cytometry analysis of
protein display and antigen recognition by p1-1 and p13B1 in scFv
and scTGP formats. Table I shows mean fluorescent intensity (MFI)
values for dot blots and includes comparison with control antigens.
The display levels for the scFv or scTGP were measured using labeled
anti-SV5 IgG (Hanke et al., 1992), an antibody recognizing a peptide
tag (SV5) at the C terminus. Data presented in Supplementary Fig.
S1, available at PEDS online, shows that 2 days of induction is more
suitable for scTGP display. The display levels for scTGP formats were
reduced by 50–80% compared to the smaller scFv protein format.
As expected, the antigen recognition signal was correspondingly
reduced. The specific peptide recognition for scTGP p1-1 was about
5% of the recognition signal of the scFv. The pattern was similar for
the p13B1 antibody as well and showed nearly 50% reduction in
display level and associated drop in signal for antigen recognition.
The affinity measurements for scFv and scTGP antibodies showed
that despite the reduction in recognition signal the calculated Kd
values were similar (within 4-fold) between the formats for a given
antigen.

Comparing cytoplasmic and periplasmic scTGP
expression systems
The scFvs are commonly expressed in the periplasmic space of the
bacterial cell, since this provides the oxidizing environment required
(Kipriyanov et al., 1997). However, higher levels of recombinant protein expression are usually observed in the E. coli cytoplasm. Therefore, we evaluated both compartments for scTGP protein expression using two different protein expression vectors. As shown in
Fig. 3A and B, the cytoplasmic expression system (pETCK3) produced a statistically significant higher amounts of fluorescent protein
in the soluble fraction after lysis compared to the periplasmic expression system. Furthermore, scTGP constructs expressed in the cytoplasm were more functional than those expressed in the periplasm, as
assessed by the specific binding activity of the two formats (Fig. 3C).
The recognition signal for specific antigen is more than three times
higher than the signal for control antigen. Based on these results,
further bacterial expression was carried out in the E. coli cytoplasm
using the pETCK3 vector system.

Comparing expression levels and functionality of scFv
and scTGP constructs
Three scFvs and corresponding scTGPs were used in protein purification and functionality studies. All six protein variants were expressed
in 1 l culture volumes, purified using Ni-NTA agarose beads (see
methods) in parallel and eluted using identical volumes. Eluates were
run on a protein gel to compare relative protein production levels.
The Coomassie staining of the protein gel showed scFv and scTGP
protein yield was comparable in the case of the p1-1 and p13B1
antibodies. The scTGP format significantly improved soluble yield
of the αTyrS antibody (Fig. 4A), consistent with relative total protein
quantification (Table II). The relative amount of protein degradation
appears to be similar between the scFv and its respective scTGP
construct.
The functionality of both antibody formats (scFv and scTGP)
was assessed using ELISA against specific and non-specific antigens
(Fig. 4B) using equal concentrations of the corresponding scFvs and
scTGPs. ITAM peptides p123 and p1 were used as specific antigens
for scFv/scTGP p13B1 and p1-1, respectively. Fibrinogen was used
as the specific antigen for the anti-tyrosine sulfate antibody (Kehoe
et al., 2006). The p0 ITAM peptide and all non-cognate targets
provide negative controls. The results showed that both the scFv and
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Display level (MFI) (SV5-PE)
Recognition signal for specific target
(MFI) (biotinylated
target-streptavidin A633)
Recognition signal for non-specific
target M2 (MFI) (biotinylated
target-streptavidin A633)
Recognition signal for secondary
only (no bio peptide) (MFI)
(streptavidin A633)
Kd values for specific antigen (nM)

scFv p1-1
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Table II. Comparison of scFv and scTGP yield from 1 l of bacterial
culture following Ni-NTA puriﬁcation
Antibody name
p1-1
p13B1
αTyrS

scFv (mg)

scTGP (mg)

4.3
5.5
0.7

6.9
6.9
6.0

scTGP format of the antibodies were functional and recognized the
expected specific antigen with comparable recognition signals and
the recognition signal for specific antigen is more than three times
higher than signal for control antigen. The specificity of the scTGP
antibodies were further investigated using a FLISA (Velappan et al.,
2008). The results showed that recognition of binding by scTGP
can be assayed using fluorescence and all three antibodies showed
specific recognition of their target antigen (Fig. 4C). Data presented
in Supplementary Fig. S2, available at PEDS online, show that at
equimolar concentration scFv and scTGP formats of p1-1 and p13B1
provide equivalent binding signals.

Crystallization and structure determination
Previous attempts to crystallize the p1-1 scFv were unsuccessful and
we hypothesized that incorporation into the scFP format would
promote crystallization. Large (>300 μm), green-colored rod-shaped
crystals of scTGP p1-1 were observed in several conditions in the
initial screening trials but did not diffract beyond 4 Å. Later, bipyramid–shaped crystals of scTGP p1-1 formed with 1.6 M citric
acid pH 6.2 as crystallization buffer after 2 months. These crystals
diffracted to better than 2.5 Å resolution and belonged to the P41 21 2
space group with cell dimensions of a = b = 130.96 Å, c = 122.74 Å.
The complete data set has an Rmerge of 5.9% for the resolution range
of 50–2.5 Å. Cell content analysis gave a Matthews coefficient of 3.17

Å3 Da−1 and a solvent content of 61% with one copy of scTGP p1-1
molecule in the asymmetric unit. The final Rwork and Rfree values
were 16.3% and 21.1%, respectively. The refined structure contains
1 scTGP p1-1, 2 glycerols, and 136 water molecules. Detailed data
collection and refinement statistics are listed in Table III. The atomic
coordinates and structure factors are available in the RCSB Protein
Data Bank under accession code 6WZN.
Figure 5 shows the crystal structure of scTGP p1-1, which
revealed a single-chain protein with three distinct domains, the TGP
domain (residues 119–335) and the scFv VL (residues 1–112) and VH
(residues 346–465) domains. The linker residues 113–118 formed a
short α-helix between the scFv VL domain and the N-terminal of
TGP. Residues 336–345 linking the C-terminal of TGP to the scFv
VH domain have relatively poor electron densities indicating partial
disorder. Two glycine residues (338–339) in this linker were not
modeled.
The TGP structure was used as the MR search model and as
the initial structure of the TGP domain in scTGP p1-1 structural
refinement. When superposed together, the Cα root-mean-square
deviations (RMSD) between the refined TGP domain (this work)
and the four individual protomers in the TGP structure range from
0.24 to 0.41 Å. As expected, several FP structures such as PDB IDs:
4PPL, 5EBJ, 2GX2 have RMSDs within this range when superposed
with the TGP domain of scTGP p1-1. This is consistent with the
well-conserved sequence of these proteins (>90% identity) in this FP
family.
The structures of the VH and VL domains of this scTGP are also
well conserved with structures in the Fab structure family such as PDB
IDs: 1RZG and 3UX9. The superposed Cα RMSDs are about 0.5 Å
between the VL domain of scTGP and similar light-chain structures
and are 0.6–0.7 Å between heavy-chain structures. Cysteines 367 and
441 in the VH domain are in close proximity to each other. They did
not form a disulfide bond as most of the corresponding cysteine pairs
did in similar structures listed in Supplementary Table S1, available at
PEDS online, except the VH domain of PDB ID: 4NIK (Robin et al.,
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Fig. 2 Yeast display–based analysis of scFv and scTGP constructs for display level and recognition of speciﬁc antigen. The scFv and scTGP versions of two
antibodies, p1-1 and p13B1, were cloned into the pDNL6 yeast display vector and protein display induced. Protein display levels were assayed using PE conjugated
anti-SV5 antibody in panel A. In panel B, binding of scTGPs to their corresponding targets using the green ﬂuorescence (FITC-A) of the TGP as a detection modality
(instead of SV5) is shown in the x-axis. The y-axis shows the recognition of the biotinylated peptide bound to streptavidin Alexa 633. In the case of the displayed
scFvs target binding is shown, but no display as measured by TGP ﬂuorescence.
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2014). This could be attributed to, in part, the reducing environment
provided in protein purification processes.

and YP8 antibodies compete for the same epitope, as displacement
of scTGP YP8 was observed in the presence of IgG YP8 and IgG YP3
(Fig. 6D). These results were confirmed by ELISA and flow cytometry
experiments (Lillo et al., 2020).

Epitope binning using scTGPs
We show that scTGPs could be successfully used for epitope binning
of antibodies recognizing the recombinant chimeric Y. pestis F1V
protein (causative agent of plague). Here, the effect of unlabeled
IgGs on scTGPs binding was used to determine whether the two
antibody formats bind to same or different epitopes, in a one-step
assay (Fig. 6A). An scTGP-F1V binding curve (Fig. 6B) was used
to estimate the half-saturating concentration of scTGP, optimal for
detection of scTGP displacement. Figure 6C and D each show the
results of competitive epitope binning assay for anti-F1V antibodies
YP2, YP3 and YP8. Binding of scTGP was detected by fluorescence in
the presence of non-fluorescent IgGs. Results suggest that antibody
YP2 has a different epitope than YP3 and YP8 (Fig. 6C), since
no displacement of scTGP YP2 (i.e. lowering of fluorescence) is
observed in the presence of IgG YP3 and IgG YP8. As expected,
IgG YP2 displaced the scTGP YP2. The data also show that YP3

Discussion
A major problem with the use of antibodies in research and diagnostics has been their inconsistency, particularly lot-to-lot variation in
polyclonals (Bradbury and Pluckthun, 2015; Schumacher and Seitz,
2016; Slaastad et al., 2011; Weller, 2016). However, monoclonals
have also been found to be problematic (Vaezi et al., 2014), in some
cases due to the expression of additional chains in hybridomas (Bradbury et al., 2018), reflecting the uncharacterized nature of most commercial antibodies, including monoclonals (Bradbury et al., 2018). In
contrast to polyclonal antibodies from animal immunization campaigns, recombinant antibodies are expressed from defined plasmids
where the sequences of the VH and VL genes are known. Recombinant antibodies can be obtained from hybridomas by cloning the
VH and VL genes (Bradbury et al., 2018; Ruberti et al., 1994),
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Fig. 3 Assessing protein expression systems for scTGPs. The scFv format of the antibodies is expressed in the periplasmic protein expression vector, pEP. The
scTGP (scFP) format of the constructs was expressed in both pEP (periplasmic expression) and pETCK3 (cytoplasmic expression). Panel A shows the ﬂuorescence
obtained after protein expression in both vector systems using the corresponding scFv constructs as controls. The upper panel B shows ﬂuorescence from
100 μl of cell culture after two nights of protein expression (pre-lysis). The lower panel B shows ﬂuorescence for equal volume of POP culture supernatant (postlysis). The error bars were generated from three independent protein expressions. Panel C shows the functionality of scTGPs produced in the periplasmic and
cytoplasmic compartments. Two scTGPs (p1-1 and p13B1) were analyzed by FLISA for binding to their cognate antigen (ITAM p13 peptide) using M2 peptide of
inﬂuenza A as negative control. The activity of the scTGPs produced in the cytoplasm (green) was normalized to the activity of scTGP produced in the periplasm
(orange) in two different ways: equal volume (light green) or equal ﬂuorescence (dark green). ∗ denotes a p value ≤ to 0.05. The error bars represent standard
deviation generated from three independent binding assays.
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Fig. 5 Crystal structure of scTGP p1-1 (left). The sequence and secondary structure assignments of the structure (right). Residues 338–339 in the linker between
TGP and VH are disordered.

as well by selecting from large combinatorial antibody libraries
displayed on phage and/or yeast (Bradbury et al., 2011; Marks et al.,
1991). Finally, scFv can be converted into full IgGs identical to

animal-derived antibodies. A significant advantage to using display
technologies to select antibodies is that the genes encoding the
VH and VL genes are obtained concurrently with selection of the
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Fig. 4 Protein puriﬁcation and functionality assays. Panel A shows scFv and scTGP proteins puriﬁed using Nickel NTA 6× HIS tag from a 1-l culture volume. The
scFvs run slightly above 25 kDa, while scTGP run at ∼50 kDa. Panel B shows a comparison of the functionality of scFv and scTGP by ELISA. Panel C shows that
only scTGPs are functional in FLISA assays. Data for three different antibodies (p13B1, p1-1, αTyrS) with binding proﬁles against four different antigens (one
speciﬁc, and three non-speciﬁc—ITAM peptides p0, p123, p1 and ﬁbrinogen) are shown. The ELISA/FLISA assays were performed in triplicate and error bars
refer to standard deviation.
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antibody specificity, making the generation of potentially useful
derivatives relatively straightforward. Apart from reformatting as
full-length IgGs (Persic et al., 1997), VH and VL genes can be
transformed into dimerizing (De Kruif and Logtenberg, 1996) or
multimerizing (Dübel et al., 1995; Hudson and Kortt, 1999) antibody
fragments, as well as novel functional entities generated by fusion
to enzymes, tags (Cloutier et al., 2000) or fluorescent proteins
(Casey et al., 2000). While antibody fragments selected from display
libraries have been reformatted as full-length antibodies for catalog
sale (Kehoe et al., 2006), the potential utility of other formats as
commercial therapeutics has been limited.
One particularly useful format enabled by the work described
here is recombinant intrinsically fluorescent antibodies, which have
the potential to be widely used in flow cytometry and immunofluorescence. These could replace chemically labeled fluorescent antibodies, which suffer from a number of problems including variability in labeling efficiency, inactivation and quenching (Haugland, 1995; Vira et al., 2010). In this study, we build on previous
efforts (Markiv et al., 2011a,b) aimed at ameliorating these problems
by showing that: (i) the VL-FP-VH orientation can also be used
(in addition to the original VH-FP-VL orientation); (ii) additional
scFvs can be effectively modified in this way; (iii) suitable FPs are
not limited to those described by Markiv et al. but also include
TGP, an extremely stable monomeric fluorescent protein (Close
et al., 2015); (iv) scFPs can be effectively displayed on yeast, where
they function similarly to their corresponding scFv counterparts,

opening the possibility to selecting variants with improved properties either directly from naïve, or preselected, libraries; and (v)
functional expression levels of scFPs in the bacterial cytoplasm are
relatively high and can rescue some scFvs otherwise expressed at
low levels in the periplasm. This was particularly true of the antiTyrS scFv, which has been challenging to use in the past due to
poor expression levels and a propensity to aggregate. The expression
level of the scFP version was dramatically higher than the scFv
version, increasing by nearly 10-fold (6 vs 0.7 mg/ml). While we
have previously demonstrated the value of TGP as a fluorescent
protein (Close et al., 2015), we have not compared the properties
of scFPs made using TGP with others such as sfGFP or those used
by Markiv et al. (2011a,b) (monomeric red fluorescent protein;
blue, cerulean and citrine fluorescent proteins). The ability to crystallize one scTGP construct, as well as express the others within
the normal E. coli cytoplasm (i.e. without the need for specialized
strains with thioredoxin reductase and glutathione reductase mutations), suggests increased stability of the scTGP construct. However, further experiments to confirm this increased stability will be
required.
TGP is a monomeric fluorescent protein amenable to crystallization. These features provide unique and valuable characteristics to
scTGP molecules for their use in protein chemistry. In addition to
utility in downstream assays such as immunofluorescence and flow
cytometry, the intrinsic fluorescence of the molecules allows straightforward assessment of expression levels, monitoring of protein
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Fig. 6 Epitope mapping using scTGPs. The rationale behind epitope binning using scTGPs and IgGs is depicted in panel A. Here, the scTGP (green star) is allowed
to bind to a dimeric protein. Upon addition of unlabeled IgG (red oval) scTGP is either displaced (lowering the amount of ﬂuorescence) or remains the same
(unchanged ﬂuorescence). These two scenarios indicate IgG competition for the same epitope or IgG recognition of a different epitope, respectively. Panel B
shows an example of a scTGP-F1V binding curve that was used to determine suitable non-saturating amount of scTGP needed for the epitope binning assay (in
this case 5000 ng). Panel C and D show scTGP binding (ﬂuorescence) in the presence of increasing concentrations of IgG (0–50 μg). The dots represent average
ﬂuorescence values with corresponding standard deviations (error bars). Panel C shows the displacement of the scTGP 2 by IgGs YP2 and lack of displacement
by YP3 and YP8. Panel D shows the displacement of scTGP 8 by IgGs YP3 and YP8. For panels B, C, D two per moving average trend line is given as solid line
and the line is extended to last value using dotted line.
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Table III. Data collection and reﬁnement statistics for scTGP p1-1

1.0
50–2.50 (2.50–2.54)
P41 21 2
a = b = 103.96, c = 122.74
3 33 231
24 030 (1177)
100.0 (100.0)
13.9 (13.7)
5.9 (100.0)
0.019 (0.467)
0.062 (1.000)
34.51
40.3 (1.7)
50.00–2.50 (2.59–2.50)
91.85 (75.20)
21 973 (1771)
1839 (150)
0.1630 (0.2343)
0.2111 (0.2711)
136
2 GOL
0.006
0.84
43.74

98.90
1.10

Values in parentheses represent the outermost resolution shell.
a
Rmerge =  hkl  i |Ii (hkl) − <I(hkl)>|/ hkl  i Ii (hkl) where Ii (hkl) is the
intensity of the ith observation and <I(hkl)> is the mean intensity of the
reflections. The values are for unmerged Friedel pairs.
b
Rp.i.m. (precision-indicating Rmerge ) and Rmeas /Rr.i.m. (redundancyindependent Rmerge ).
c
The crystallographic R factor R =  hkl | |Fobs | − |Fcal | |/ hkl |Fobs |;
Rfree =  hkl | |Fobs | − |Fcal | |/ hkl |Fobs | where all reflections belong to a test
set of randomly selected data.

purification steps, and antigen recognition. The one step FLISA
utilized here saves time and improves the utility of antibodies
produced in this format. We also describe the use of the scTGP
proteins for epitope binning, a useful and easy technique if the antigen
is multimeric that capitalizes on the monomeric and fluorescent
properties of the scTGP constructs to assess and develop noncompetitive sets of antigen detection proteins. IgGs in general have
higher affinity for the antigen than the corresponding scFvs, since
IgGs have two copies of VH-VL and scFPs have one. Therefore,
eventual competition between the two antibody formats is strong and
easy to detect. Our ongoing work includes development of an LFAbased detection system for plague using antibodies YP2 and YP8,
identified as orthogonal binder pairs using the scTGP displacement
assay described here (Lillo et al., 2020).
A critical result obtained in this study was the observation that
the affinity values for the scFv and scTGP formats of the antibodies
were very similar, providing an additional indication that the addition
of fluorescent protein added utility without decreasing antibody
functionality. However, the display levels of scTGP on the yeast
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Data collection statistics
Wavelength (Å)
Resolution range (Å)
Space group
Unit-cell parameters (Å)
Total reflections
Unique reflections
Completeness (%)
Multiplicity
Rmerge a (%)
Rp.i.m b
Rmeas /Rr.i.m b
Wilson B factor
Average I/σ (I)
Refinement statistics
Resolution (Å)
Completeness (%)
Working reflections
Test reflections
Rwork c (%)
Rfree c (%)
No. of waters
No. of other solvent molecules
R.M.S. deviations from ideal geometry
Bonds (Å)
Angles (◦ )
Average B factors (Å2 )
Ramachandran analysis by
MOLPROBITY
Residues in favored regions (%)
Residues in allowed regions (%)

surface were significantly lower compared to the display of the
scFv and required additional induction time (∼48 vs 12–16 h for
scFvs) to increase the fluorescence of yeast displaying scTGPs by
∼20%, as shown in Supplementary Fig. S1, available at PEDS online.
This extended time likely reflects the need for additional time to
fold the larger scFP molecules, or mature the fluorophore, and may
vary depending upon the scFv sequence. Therefore, the development
of high-throughput methods to select scFvs suitable for conversion
to scTGP would be highly advantageous. Interactions between the
folding of the FP and the VH, VL domains are difficult to predict.
For example, yields may be improved by other robustly folding
fluorescent proteins such as superfolder GFP (Pédelacq et al., 2006),
which was specifically selected to avoid interfering with the folding of
fused domains. The availability of several, alternative, robustly folded
fluorescent proteins to serve as linkers should extend the applicability
of the approach described (Velappan et al., 2020).
Attempts to obtain crystal structures of scTGP complexed with
3 versions of the 17mer antigen peptides were unsuccessful. The
17mer peptide sequence was LYEELHVYSPIYSALED and peptides
containing the first tyrosine phosphorylated (p1-17), the second
tyrosine phosphorylated (p2-17), and both first and second tyrosines
phosphorylated p12-17 were selected for crystallization experiments
based on ELISA, FLISA and flow cytometry studies with peptides
of varying lengths. Over 800 screening conditions were attempted
to obtain co-crystals of scTGP and these peptides but resulted in no
crystal hits. Soaking apo-scTGP crystals in peptide-containing mother
liquors shattered and dissolved crystals almost instantaneously, and
crystal pieces harvested after flash-soaking in these solutions did
not diffract. These observations suggest that strong interactions
exist between scTGP and its antigen peptides. Such interactions are
likely to induce substantial conformational changes between the
scFv domains causing deformation of the crystal lattice of the aposcTGP crystal. The bound peptides could also interfere with crystal
formation in the case of co-crystallization trials. Systematic peptide
construct screening may be required to obtain the co-crystals of the
scTGP and its antigen peptides.
One of the major problems faced by scFvs identified using display
technologies is the quality, quantity and stability of purified scFv
protein available for downstream characterization. E. coli periplasmic expression produces limited quantities of scFv, which can lead to
poorly purified, aggregated and unstable protein (Arbabi-Ghahroudi
et al., 2005; Arndt et al., 1998), which is why scFvs are not widely
used as research reagents. N- and C-terminal FPs require additional
flexible linkers that are prone to proteolytic cleavage resulting in
potential decoupling of binding from fluorescence. scFv constructs
use a flexible linker to connect the VL and VH regions of the scFv,
while in naturally occurring IgGs, the VH/VL interaction is stabilized
by CH1 and CL. It is possible that the use of a fluorescent protein
as connector between the VL and VH domains of a scFv may promote greater stability by mimicking the Fab architecture of natural
IgGs, while also providing the added biotechnological functionality
of intrinsic fluorescence. The additional stability provided in this
orientation relative to N- and C-terminal constructs may promote
crystallization through minimization of interdomain flexibility. The
crystal structure reported here provides some evidence to support this
concept, as the scFv version of the scFP was previously refractory to
crystallization, and within the structure, the TGP is found in close
proximity to the lower scFv interface. In conclusion, we report that
the scTGP format holds promise for the development of robust and
readily expressible antibody fragments with a wide variety of uses in
research and clinical settings.
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